Download PDF
CC BY 4.0 · Indian J Med Paediatr Oncol
DOI: 10.1055/s-0045-1809446
Brief Communication

First Report of a Novel Unbalanced Complex Variant Translocation t(3;9;22) with Ph Duplication and Evolving Triple Trisomy (8,12,21) in Newly Diagnosed Chronic Myeloid Leukemia without Blast Crisis: Resistance to Frontline Therapy

Suhaib Mohammad Ali Abunaser
1   Bahrain Oncology Center, Busaiteen, Kingdom of Bahrain
,
Shruti Prem Sudha
1   Bahrain Oncology Center, Busaiteen, Kingdom of Bahrain
,
Anurita Pais
1   Bahrain Oncology Center, Busaiteen, Kingdom of Bahrain
› Author Affiliations
Funding None.
› Further Information
Also available at
  Permissions and Reprints

Abstract

In chronic myeloid leukemia (CML), tyrosine kinase inhibitors (TKIs) targeting the BCR/ABL1 fusion gene have transformed CML into a manageable condition. While most cases involve the standard t(9;22) translocation, 5 to 10% exhibit variant translocations and/or additional chromosomal abnormalities (ACAs), often linked to disease progression. Hence, cytogenetic analysis is crucial for monitoring clonal evolution and guiding treatment.

This report presents a unique case of chronic-phase CML with a three-way unbalanced variant translocation involving chromosomes 3, 9, and 22, alongside an interstitial deletion of the reciprocal ASS1/ABL1/BCR region. ACAs with Ph duplication and trisomy of chromosomes 8, 12, and 21 in the present case complicate the genomic landscape, with specific breakpoint involvement and additional abnormalities indicating a poorer outcome, highlighting the need for further investigation and tailored treatment strategies.

Given the rarity and poor prognostic association of this finding, our study highlights the importance of identifying complex chromosomal variations to enable modified targeted therapy regimens as first-line treatment. This emphasizes the need for individualized prognostic assessment and continuous monitoring to optimize therapeutic outcomes.

Keywords

chronic myeloid leukemia - variant translocation - karyotype - fluorescence in situ hybridization - imatinib - ponatinib

Author's Contributions

S.M.A.A.: concept, design, experimental studies, data analysis, manuscript preparation, manuscript editing, and manuscript review.


S.P.S.: clinical study, data analysis, manuscript preparation, manuscript editing, and manuscript review.


A.P.: concept, literature search, data analysis, manuscript preparation, manuscript editing, and manuscript review.


Patient Consent




Publication History

Article published online:
06 June 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 El-Tanani M, Nsairat H, Matalka II. et al. The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia. Pathol Res Pract 2024; 254: 155161
    PubMedSearch in Google Scholar
  • 2 Xue M, Cheng J, Zhao J. et al. Outcomes of 219 chronic myeloid leukaemia patients with additional chromosomal abnormalities and/or tyrosine kinase domain mutations. Int J Lab Hematol 2019; 41 (01) 94-101
    PubMedSearch in Google Scholar
  • 3 Clark RE, Apperley JF, Copland M, Cicconi S. Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression. Blood Adv 2021; 5 (04) 1102-1109
    CrossrefPubMedSearch in Google Scholar
  • 4 Bayrak AG, Daglar Aday A, Yavuz AS. et al. Overview of clinical and genetic features of CML patients with variant Philadelphia translocations involving chromosome 7: a case series. Leuk Res 2021; 111: 106725
    PubMedSearch in Google Scholar
  • 5 Iglesias A, Oancea R, Cotarelo C, Anguita E. Variant Philadelphia t(X;9;22)(q22?q34;q11.2) can be successfully treated with second generation tyrosine kinase inhibitors: a case report and literature review. Biomed Rep 2021; 15 (04) 83
    PubMedSearch in Google Scholar
  • 6 Takeuchi A, Kondo T, Tasaka T. et al. Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1 . Leuk Res Rep 2020; 15 (15) 100233
    PubMedSearch in Google Scholar
  • 7 Li Q, Lin XJ, Chen H, Gong J, Li Z, Chen XN. Co-existence of isodicentric Ph chromosomes and the three-way Ph chromosome variant t(3;9;22)(p21;q34;q11) in a rare case of chronic myeloid leukemia. Oncol Lett 2018; 15 (04) 4599-4603
    PubMedSearch in Google Scholar
  • 8 Ansari S, Verma M. Control of Ph+ and additional chromosomal abnormalities in chronic myeloid leukemia by tyrosine kinase inhibitors. Med Oncol 2023; 40 (08) 237
    PubMedSearch in Google Scholar
  • 9 Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer. Accessed May 22, 2025 at: http://cgap.nci.nih.gov/Chromosomes/Mitelman
  • 10 Tan J, Cang S, Seiter K. et al. t(3;9;22) 3-way chromosome translocation in chronic myeloid leukemia is associated with poor prognosis. Cancer Invest 2009; 27 (07) 718-722
    PubMedSearch in Google Scholar
  • 11 Chandran RK, Geetha N, Sakthivel KM. et al. Prognostic implications of derivative chromosome 9 deletions in patients with advanced-stage chronic myelogenous leukemia. J Environ Pathol Toxicol Oncol 2018; 37 (02) 117-126
    PubMedSearch in Google Scholar
  • 12 Hemsing AL, Hovland R, Tsykunova G, Reikvam H. Trisomy 8 in acute myeloid leukemia. Expert Rev Hematol 2019; 12 (11) 947-958
    PubMedSearch in Google Scholar
  • 13 Chen CC, Silberman RE, Ma D. et al. Inherent genome instability underlies trisomy 21-associated myeloid malignancies. Leukemia 2024; 38 (03) 521-529
    PubMedSearch in Google Scholar